BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
📌TL;DR
AbbVie (ABBV) agreed to acquire Apogee Therapeutics (APGE) for $10.9B in cash ($135.11 per share, 49% premium), picking up zumilokibart, a long acting anti IL 13 antibody for eczema and asthma that could need as few as two to four injections per year. That compares to every two weeks for Sanofi and Regeneron's Dupixent, which generated $14B in 2025 revenue. This is AbbVie's biggest acquisition since the $63B Allergan deal in 2020.
The deal brings the number of 2026 biotech deals over $1B to 33, with the total now just under $134B. ABBV shares rose 6.9%.
Merck's tulisokibart met primary and key secondary endpoints in the Phase 3 ATLAS UC study in patients with moderately to severely active ulcerative colitis, according to StockTitan.
BIO International Convention is underway in San Diego (June 22 to 25) with more than 20,000 attendees and 130 sessions across 18 focus areas.
⚡ Executive Takeaway
AbbVie knows immunology better than almost anyone. Humira made the company more than $200B before it went off patent. Skyrizi and Rinvoq are growing faster than Humira is declining. And now zumilokibart gives AbbVie a shot at the next generation of eczema and asthma treatment with a dosing profile that could reshape how patients think about their disease.
The math is simple. Dupixent requires an injection every two weeks. That's 26 shots a year. Zumilokibart's Phase 2 data support dosing every three to six months. That's two to four shots a year. If the efficacy holds in Phase 3 (studies start this year), the convenience advantage is enormous. Guggenheim doubled their peak sales estimate to $5.2B after the Phase 2 data in March. BMO said the deal "fits naturally" with AbbVie's portfolio.
What makes this interesting is the timing. Just three weeks ago, Apogee locked in $1.3B in non dilutive financing from Blackstone to fund zumilokibart development on its own. Three weeks later, AbbVie showed up with $10.9B and ended the conversation. Blackstone's investors are having a good morning.
Yale's Dr. Christopher Bunick said the deal "is going to send shock waves through the AD community." BioPharma Dive noted this is AbbVie's third company buyout since late January and the sector's second largest deal of 2026 behind GSK's $10.6B Nuvalent acquisition.
🚀 Top Story
AbbVie Acquires Apogee for $10.9B to Challenge Dupixent ABBV | APGE
AbbVie announced Monday that it will acquire Apogee Therapeutics for approximately $10.9B in an all cash tender offer at $135.11 per share, a 49% premium to the June 18 closing price. Both boards unanimously approved the transaction, which is expected to close in Q3 2026.
Zumilokibart is an extended half life anti IL 13 monoclonal antibody being developed for atopic dermatitis, asthma, and other inflammatory conditions. In Phase 2, approximately two thirds of patients achieved significant skin clearance at 16 weeks with concurrent improvement in itch and disease control. The longer term data support maintenance dosing of either once every three months or twice a year.
Fierce Biotech reported the deal "will give AbbVie control of a late phase eczema drug candidate that could pose a threat to Eli Lilly, Regeneron and Sanofi." Cross trial comparisons suggest zumilokibart can match or improve on the efficacy of Lilly's Ebglyss and Sanofi/Regeneron's Dupixent while dramatically reducing injection frequency.
AbbVie's immunology franchise (Skyrizi, Rinvoq, Humira successor portfolio) gives the company deep commercial infrastructure in dermatology and respiratory medicine. JPMorgan said AbbVie will be able to "leverage its historic strength in immunology" to push zumilokibart through Phase 3 and commercialization.
🔬 Clinical
Merck's Tulisokibart Hits Phase 3 in Ulcerative Colitis MRK
Merck announced that tulisokibart met the primary and key secondary endpoints in the Phase 3 ATLAS UC induction study in patients with moderately to severely active ulcerative colitis. Tulisokibart is an anti TL1A antibody, a mechanism that has attracted significant industry interest following Roche's acquisition of Telavant ($7.1B) for the same target. The positive data give Merck a strong entry into the growing inflammatory bowel disease market and add to the company's pipeline diversification beyond Keytruda.
📊 By the Numbers
The AbbVie/Apogee deal pushes 2026 M&A further into historic territory:
33 deals over $1B this year. Total value just under $134B. That's up from the $106B CNBC reported three weeks ago. The pace shows no sign of slowing with BIO International underway in San Diego and hundreds of partnering meetings happening this week.
For context: PwC's midyear report called the ecosystem "back to full health." Forbion said companies are "buying stuff like it's going out of fashion." AbbVie proving both right with its third billion dollar plus acquisition of 2026 (after RAPT Therapeutics and 35Pharma earlier this year).
📅 Coming Up
Now through June 25: BIO International Convention (San Diego)
July 1: Medicare GLP-1 Bridge program launches (8 days)
July 31: Section 232 pharma tariffs effective for large companies
Imminent: Revolution Medicines CNPV NDA filing
Imminent: Lilly Foundayo T2D filing under CNPV
🔓 BioMed Nexus Pro: Institutional Intelligence Brief
🧠 The Dosing Advantage
Dupixent is a great drug. It generated $14B in 2025 across eczema, asthma, CRSwNP, and other indications. But it requires injection every two weeks, indefinitely. For a chronic disease that often begins in childhood and lasts a lifetime, that adds up to hundreds of injections.
Zumilokibart's extended half life means it stays active in the body much longer. Phase 2 data support quarterly or twice yearly dosing. If Phase 3 confirms this, the patient experience changes fundamentally. Instead of a biweekly routine, patients would visit their physician two to four times a year.
This matters for adherence. Real world studies consistently show that injection fatigue drives discontinuation rates of 20% to 30% annually for biweekly biologics. A drug that maintains the same efficacy with 85% to 90% fewer injections should see meaningfully better persistence, which translates directly to sustained clinical outcomes and recurring revenue.
Guggenheim's $5.2B peak sales estimate reflects this logic. Dupixent at $14B with biweekly dosing. Zumilokibart potentially capturing a significant share with superior convenience. Even a 30% to 40% share of the addressable market gets you to $5B.
💊 Anti TL1A: The IBD Race
Tulisokibart joins a crowded but commercially massive space. TL1A is emerging as one of the most important new targets in inflammatory bowel disease:
Roche paid $7.1B for Telavant's RVT 3101 (anti TL1A) in 2024. Prometheus (now Merck via acquisition) had the first strong Phase 2 data. Now Merck's Phase 3 confirms the mechanism works at the registrational level.
The IBD market is projected to exceed $30B by 2030. Current biologics (Humira biosimilars, Entyvio, Stelara, Skyrizi, Rinvoq) are effective but leave substantial unmet need, particularly in patients who cycle through multiple therapies. Anti TL1A offers a new mechanism with potential for broader and deeper response.
📊 AbbVie 2026 Deal Activity
AbbVie has now executed three significant acquisitions in 2026:
Deal | Value | Area |
|---|---|---|
RAPT Therapeutics | $2.2B | Immunology (January) |
35Pharma | $950M | Oncology (February) |
Apogee Therapeutics | $10.9B | Eczema/Asthma (June) |
Total: approximately $14B deployed. AbbVie also raised its 2026 outlook (May), settled Rinvoq patents to 2037, and entered the KRAS space through its $1.45B Kestrel option deal. The company is executing across immunology, oncology, and pipeline defense simultaneously.
Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →
Sponsorship slots for 2026 are limited. See packages and pricing →
NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →